Monte Carlo is generally accepted as the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, Monte Carlo accuracy is now available for secondary independent dose calculation and verification, allowing users to verify the most advanced treatment plans with an equally robust QA solution.
At this year’s AAPM in Nashville we received exceptionally positive feedback from the medical physics communityJean-Marc Bothy
SciMoCa’s design and implementation have been optimized for clinical efficiency and workflow simplicity. Workflow integration and automation ensure seamless application of Monte Carlo QA for clinical needs, allowing patients of all major treatment modalities to benefit from Monte Carlo accuracy without the time-consuming operations of “academic” Monte Carlo solutions of the past. Comprehensive verification tools such as comparative DVH review, 3D gamma analysis and plan quality reporting enable fast and intuitive treatment plan QA.
“IBA has always strived to provide cutting edge QA solutions to improve cancer treatments and safety for radiation therapy patients. Introducing Monte Carlo plan QA seamlessly for all major Linacs, TPS systems and treatment modalities introduces an additional level of QA accuracy in our industry,” said Jean-Marc Bothy, President of IBA Dosimetry GmbH. “At this year’s AAPM in Nashville we received exceptionally positive feedback from the medical physics community about SciMoCa’s unprecedented Monte Carlo workflow automation, calculation speed and proven accuracy”.
SciMoCa is FDA-cleared and immediately available for clinical use in the U.S. to bring secondary 3D plan QA to a new level of accuracy for all major Linacs from Varian, Elekta and Siemens, including the Accuray CyberKnife.
SciMoCa is a solution developed by Radialogica and Scientific RT. IBA has entered into a global distribution agreement with Radialogica for the SciMoCa Monte Carlo powered secondary plan calculation and verification software.
“We are delighted to enter into this agreement with IBA Dosimetry for the global distribution of SciMoCa Monte Carlo plan QA,” said Andrew Cowen, Chief Executive Officer of Radialogica. “IBA Dosimetry has established a leading position in the field of radiation therapy integrated quality assurance with a strong and global distribution network. We look forward to partnering with IBA Dosimetry to bring this important technology to patients and providers around the world.”
“With the availability of this clinically proven Monte Carlo QA solution a new era of 3D patient QA has begun,” said Prof. Dr. Markus Alber, Head of Scientific RT and Monte Carlo expert. “Recent peer-reviewed publications have proven SciMoCa’s accuracy and calculation speed, which is the basis for efficient clinical implementation.”